SCHEMBL23626100

SCHEMBL23626100

C=C(C)[C@@H]1CC[C@]2(COC(C)=O)CC[C@]3(C)C(CCC4[C@@]5(C)CC/C(=N/O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EGLN2 Q96KS0 1/20 0.67
▸ EGLN1 Q9GZT9 1/20 0.67
▸ EGLN3 Q9H6Z9 1/20 0.67
▸ P4HTM Q9NXG6 1/20 0.67
▸ GPBAR1 Q8TDU6 5/20 0.65
▸ SLC10A1 Q14973 1/20 0.58
▸ CA9 Q16790 4/20 0.56
▸ LMNA P02545 2/20 0.55
▸ NT5E P21589 2/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ PTGES O14684 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ USP2 O75604 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ TOP2A P11388 1/20 0.51
▸ PTPN1 P18031 1/20 0.51
▸ RELA Q04206 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13293199 0.91 SLC10A1 (0.58) EGLN2EGLN1EGLN3P4HTMGPBAR1
SCHEMBL13910810 0.89 GPBAR1 (0.70) GPBAR1SLC10A1CA9LMNANT5E
SCHEMBL13098061 0.89 GPBAR1 (0.70) GPBAR1SLC10A1CA9LMNANT5E
SCHEMBL23626105 0.89 GPBAR1 (0.70) GPBAR1SLC10A1CA9LMNANT5E
SCHEMBL13293191 0.86 GPBAR1 (0.67) EGLN2EGLN1EGLN3P4HTMGPBAR1
SCHEMBL13304147 0.85 SLC10A1 (0.67) EGLN2EGLN1EGLN3P4HTMGPBAR1
SCHEMBL13293224 0.84 SLC10A1 (0.60) GPBAR1SLC10A1CA9LMNANT5E
SCHEMBL13293161 0.83 EGLN2 (0.56) EGLN2EGLN1EGLN3P4HTMGPBAR1
SCHEMBL13293163 0.83 EGLN2 (0.83) EGLN2EGLN1EGLN3P4HTMGPBAR1
SCHEMBL14086933 0.83 EGLN2 (0.83) EGLN2EGLN1EGLN3P4HTMGPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192759-A1 BETULASTATIN COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-06-22 — — US disclosed
US-20230192759-A1 BETULASTATIN COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-06-22 — — US disclosed
US-20210206798-A1 BETULASTATIN COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2021-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192759-A1 BETULASTATIN COMPOUNDS PGGT1B, RABGGTB, BET1 EGLN2 3151/4885EGLN1 2310/4885EGLN3 2214/4885
US-20210206798-A1 BETULASTATIN COMPOUNDS PGGT1B, RABGGTB, BET1 EGLN2 3151/4885EGLN1 2310/4885EGLN3 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback